Clay Siegall

The headquarters of Seattle Genetics may be mistaken for a less geeky place, given its first impression of beige buildings. The only visual that changes that is the triangular sculpture that provokes the image of an antibody found in a human body. These antibodies are the focus of research at Seattle Genetics with their strength in their ability to combine them into therapy. With over 900 employees and a value of over $10b, it is one of the largest companies dealing with biotech in Washington.

The firm’s flagship drug, Adcetris, treats Hodgkin lymphoma, which is a lymph system cancer that could spread to other organs and promises significant sales if the current tests are positive. His great desire of building a great company features many drugs by the company as opposed to merely selling to bigger companies as a general biotech business would do.

Clay Siegall has such ambitious plans for moving beyond essential focus when it comes to drug creation and getting over obstacles of international marketing for their product. Formerly though, Seattle Genetics used to sell international commercial rights and thus be able to fund research for their flagship drug. Siegall since learned about how to handle international marketing from that partnership with Takeda and used the knowledge to the benefit of his company.

With determination to be a major in the market share of the global market, Clay spent $2b in the acquisition of worldwide rights of commercializing a cancer drug designed by an Immunomedics based in NJ. That advance in business move indicates the ability of the company to use its in-depth knowledge and resources to bring about their popularity in the global markets.

Dr. Seagall is a 15 patent holder with more than 70 publications who led the company to fundraise, and under his management, the growth curve of Seattle Genetics is currently in an exponential phase. Sales had come up 46% in two years since 2014. He founded the company in 1998 and since then won approval for U.S Food and Drug Administration (FDA) in 2011.

With a Ph.D. in Genetics, George Washington University, and a B.S in Zoology, University of Maryland, Seagal looks to use his expansive knowledge and diverse experience to make the company one of the global leaders in genetics studies and products. With a focus on patience, and basing his approach on innovative solutions, Clay Siegall is more than fit for the endeavor of the Seattle Genetics.